# Calliditas Therapeutics AB (CALT)

Source: https://www.quantisnow.com/company/CALT
Generated: 2026-11-11T08:05:06.073Z

- Ticker: CALT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- Website: calliditas.se

## About

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.

## Latest CALT news and filings

- 2024-09-23 20:44 UTC [SEC Form 15F-12B filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-15f-12b-filed-by-calliditas-therapeutics-ab-5702290)
- 2024-09-23 11:32 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-calliditas-therapeutics-ab-5701567)
- 2024-09-20 20:45 UTC [SEC Form 25-NSE filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-calliditas-therapeutics-ab-5701055)
- 2024-09-18 13:02 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-calliditas-therapeutics-ab-5697772)
- 2024-09-17 11:55 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-calliditas-therapeutics-ab-5695927)
- 2024-09-17 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-effect-filed-by-calliditas-therapeutics-ab-5695747)
- 2024-09-16 20:41 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-calliditas-therapeutics-ab-5695318)
- 2024-09-16 13:46 UTC [Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm](https://www.quantisnow.com/insight/delisting-of-calliditas-therapeutics-ab-publ-from-nasdaq-stockholm-5694648)
- 2024-09-13 20:18 UTC [SEC Form 25 filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-25-filed-by-calliditas-therapeutics-ab-5693467)
- 2024-09-13 20:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-calliditas-therapeutics-ab-5693438)
- 2024-09-13 20:15 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-calliditas-therapeutics-ab-5693430)
- 2024-09-13 20:15 UTC [SEC Form POS AM filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-calliditas-therapeutics-ab-5693417)
- 2024-09-11 23:42 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-calliditas-therapeutics-ab-5691036)
- 2024-09-10 00:57 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-calliditas-therapeutics-ab-5687968)
- 2024-09-04 01:55 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-calliditas-therapeutics-ab-5680725)
- 2024-09-03 20:21 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-calliditas-therapeutics-ab-5680063)
- 2024-09-03 20:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-calliditas-therapeutics-ab-5680042)
- 2024-09-03 12:22 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-calliditas-therapeutics-ab-5679183)
- 2024-09-03 11:13 UTC [Conference Announcement] [Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)](https://www.quantisnow.com/insight/notice-of-extraordinary-meeting-of-calliditas-therapeutics-ab-publ-5678892)
- 2024-09-03 10:31 UTC [Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei](https://www.quantisnow.com/insight/calliditas-therapeutics-takes-certain-corporate-actions-following-announcement-by-asahi-5678777)
- 2024-08-13 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-calliditas-therapeutics-ab-5656819)
- 2024-08-13 15:46 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-calliditas-therapeutics-ab-5656441)
- 2024-08-13 05:22 UTC [Earnings Date] [Calliditas Interim Report January to June 2024](https://www.quantisnow.com/insight/calliditas-interim-report-january-to-june-2024-5655706)
- 2024-08-05 05:19 UTC [Earnings Date] [Invitation to the presentation of Calliditas's interim report January - June 2024](https://www.quantisnow.com/insight/invitation-to-the-presentation-of-calliditass-interim-report-january---5641129)
- 2024-08-02 20:26 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-calliditas-therapeutics-ab-5640487)
- 2024-08-01 21:00 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-calliditas-therapeutics-ab-5638863)
- 2024-08-01 13:00 UTC [Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference](https://www.quantisnow.com/insight/calliditas-therapeutics-to-attend-2024-women-in-nephrology-win-leadership-5637298)
- 2024-07-31 20:42 UTC [SEC Form 6-K] [SEC Form 6-K filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-calliditas-therapeutics-ab-5635922)
- 2024-07-31 12:23 UTC [Number of shares and votes in Calliditas Therapeutics](https://www.quantisnow.com/insight/number-of-shares-and-votes-in-calliditas-therapeutics-5634684)
- 2024-07-26 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-calliditas-therapeutics-ab-5629814)
- 2024-07-26 15:21 UTC [Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy](https://www.quantisnow.com/insight/calliditas-partner-stada-receives-european-commission-decision-for-full-approval-5629593)
- 2024-07-26 06:23 UTC [Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis](https://www.quantisnow.com/insight/calliditas-announces-positive-transform-phase-2b-topline-data-in-primary-5629095)
- 2024-07-22 20:04 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-calliditas-therapeutics-ab-5620070)
- 2024-07-18 12:02 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-calliditas-therapeutics-ab-5614638)
- 2024-07-05 06:42 UTC [Market Chatter] [Reported Thursday, Calliditas Therapeutics And Viatris Initiate Phase III Clinical Trial Of Nefecon For IgA Nephropathy In Japan](https://www.quantisnow.com/insight/reported-thursday-calliditas-therapeutics-and-viatris-initiate-phase-iii-clinical-5594682)
- 2024-07-04 07:20 UTC [Conference Announcement] [Launch of Phase 3 clinical trial with Nefecon in Japan](https://www.quantisnow.com/insight/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-5594564)
- 2024-06-18 10:27 UTC [Market Chatter] [Calliditas Therapeutics Receives Patent For NOX Inhibitors For Treatment Of Cancer](https://www.quantisnow.com/insight/calliditas-therapeutics-receives-patent-for-nox-inhibitors-for-treatment-of-5563450)
- 2024-06-18 10:23 UTC [Calliditas provides setanaxib patent update](https://www.quantisnow.com/insight/calliditas-provides-setanaxib-patent-update-5563445)
- 2024-06-17 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Calliditas Therapeutics AB](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-calliditas-therapeutics-ab-5561979)
- 2024-06-17 16:01 UTC [Dividends] [Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)](https://www.quantisnow.com/insight/bulletin-from-the-annual-general-meeting-of-calliditas-therapeutics-ab-5561477)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CALT
- Earnings history: https://www.quantisnow.com/earnings/CALT
- Dividend history: https://www.quantisnow.com/dividends/CALT
- Insider transactions: https://www.quantisnow.com/insiders/CALT
- Options chain: https://www.quantisnow.com/options/CALT
- SEC 8-K filings only: https://www.quantisnow.com/company/CALT/8-k
- RSS and alerts for CALT: https://www.quantisnow.com/docs/rss-feeds.md